Skip to main content
    H

    Harvard Bioscience Inc (HBIO)

    Official site

    HEALTHCARE • MEDICAL INSTRUMENTS & SUPPLIES • NASDAQ

    $8.91
    -0.48 (-5.11%)

    Market Cap: $42.94M

    Last updated: Nov 17, 2026 at 11:03 AM ET

    Harvard Bioscience Inc (HBIO) Earnings: Report Dates and Results

    Updated Nov 10, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    In the quarter ended Sep 30, 2026, Harvard Bioscience reported EPS of -$0.16, above the -$0.65 estimate. It beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    33%(13/39)
    Avg Surprise
    +3.46%
    Streak
    1 Q

    Upcoming Estimates

    Report date not yet scheduledPeriod ending Dec 31, 2026
    EPS Consensus$0.19
    Range$0.08 - $0.32
    4 analysts
    Revenue Consensus
    $24.96M
    Range$23.91M - $25.73M
    5 analysts
    Report date not yet scheduledPeriod ending Mar 31, 2027
    EPS Consensus-$0.01
    Range-$0.01 - -$0.01
    1 analysts
    EPS Revisions
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago-$0.23+95.7%
    60d ago-$0.23+95.7%
    30d ago-$0.23+95.7%
    7d ago-$0.23+95.7%
    Current-$0.01
    Revenue Consensus
    $23.50M
    Range$23.50M - $23.50M
    1 analysts

    Next Report

    HBIO's report for the quarter ending Dec 31, 2026 is not on the earnings calendar yet.

    HBIO Earnings Call

    The latest HBIO earnings call transcript on file is labeled 2026Q3.

    Read the 2026Q3 transcript

    Earnings History

    Of the 39 quarters below that had an estimate, HBIO beat 13, missed 19 and matched 7. Revenue for the quarter ended Sep 30, 2026 was $22.20M, up 7.8% from $20.59M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$0.16-$0.65N/A+75.38%BeatN/A21 up, 0 downNov 10, 2026$22.20M
    Jun 30, 2026-$0.22-$0.21-$0.35 - -$0.07-4.76%MissN/A20 up, 1 downAug 11, 2026$22.73M
    Mar 31, 2026-$0.77-$0.95N/A+18.95%BeatN/A10 up, 1 downMay 12, 2026$20.75M
    Dec 31, 2025-$0.64$0.04$0.03 - $0.04N/AN/A-1695.8%20 up, 2 downMar 12, 2026$23.73M
    Sep 30, 2025-$0.03$0.05$0.00 - $0.10-160.00%MissN/A21 up, 0 downNov 6, 2025$20.59M
    Jun 30, 2025-$0.10-$0.25-$0.30 - -$0.20+60.00%BeatN/A20 up, 2 downAug 11, 2025$20.45M
    Mar 31, 2025-$0.10-$0.40-$0.60 - -$0.20+75.00%Beat-150.0%20 up, 2 downMay 12, 2025$21.77M
    Dec 31, 2024$0.04$0.05$0.04 - $0.06-20.00%Miss0.0%21 up, 1 downMar 12, 2025$24.56M
    Sep 30, 2024-$0.20$0.15$0.00 - $0.50-233.33%Miss-300.0%30 up, 0 downNov 7, 2024$21.97M
    Jun 30, 2024-$0.07$0.50$0.30 - $0.70-113.46%Miss-116.8%20 up, 0 downAug 8, 2024$23.10M
    Mar 31, 2024$0.20$0.25$0.20 - $0.30-20.00%Miss-66.7%30 up, 0 downMay 7, 2024$24.51M
    Dec 31, 2023$0.04$0.05$0.05 - $0.05-20.00%Miss0.0%30 up, 0 downMar 7, 2024$28.15M
    Sep 30, 2023$0.10$0.40$0.40 - $0.40-75.00%MissN/A30 up, 0 downNov 7, 2023$25.36M
    Jun 30, 2023$0.40$0.55$0.50 - $0.80-27.27%Miss-20.0%30 up, 0 downAug 8, 2023$28.76M
    Mar 31, 2023$0.60$0.45$0.40 - $0.60+33.33%Beat+50.0%30 up, 0 downApr 25, 2023$29.98M
    Dec 31, 2022$0.04$0.03$0.00 - $0.09+33.33%Beat-50.0%30 up, 0 downMar 9, 2023$28.43M
    Sep 30, 2022-$0.10$0.55$0.50 - $0.90-118.18%Miss-116.7%31 up, 0 downNov 8, 2022$26.92M
    Jun 30, 2022$0.50$0.55$0.30 - $0.80-9.09%Miss-16.7%30 up, 0 downAug 3, 2022$29.21M
    Mar 31, 2022$0.40$0.55$0.50 - $0.60-27.27%Miss-20.0%30 up, 0 downMay 4, 2022$28.78M
    Dec 31, 2021$0.08$0.10$0.08 - $0.13-20.00%Miss0.0%30 up, 0 downMar 8, 2022$33.05M
    Sep 30, 2021$0.60$0.60$0.60 - $0.600.00%In line+50.0%3N/ANov 3, 2021$29.66M
    Jun 30, 2021$0.60$0.65$0.50 - $0.80-7.69%Miss+20.0%3N/AAug 5, 2021$29.20M
    Mar 31, 2021$0.50$0.25$0.20 - $0.50+100.00%BeatN/A3N/AMay 6, 2021$26.99M
    Dec 31, 2020$0.08$0.07$0.06 - $0.07+14.29%Beat0.0%2N/AMar 10, 2021$30.98M
    Sep 30, 2020$0.40$0.20$0.20 - $0.50+100.00%Beat0.0%2N/ANov 5, 2020$24.04M
    Jun 30, 2020$0.50-$0.10-$0.50 - -$0.10+600.00%Beat+25.0%2N/AAug 5, 2020$23.31M
    Mar 31, 2020-$0.10$0.30$0.20 - $0.40-133.33%Miss-150.0%3N/AMay 5, 2020$23.77M
    Dec 31, 2019$0.08$0.09$0.08 - $0.10-11.11%Miss+14.3%3N/AFeb 26, 2020$30.97M
    Sep 30, 2019$0.40$0.50$0.40 - $0.60-20.00%Miss0.0%3N/ANov 5, 2019$27.42M
    Jun 30, 2019$0.40$0.40$0.40 - $0.400.00%In line-42.9%3N/AJul 25, 2019$29.58M
    Mar 31, 2019$0.20$0.35$0.30 - $0.40-42.86%Miss-33.3%3N/AMay 2, 2019$28.20M
    Dec 31, 2018$0.07$0.07$0.07 - $0.070.00%In line+40.0%3N/AFeb 28, 2019$33.86M
    Sep 30, 2018$0.40$0.40$0.40 - $0.400.00%In line+33.3%3N/AOct 25, 2018$28.64M
    Jun 30, 2018$0.70$0.53$0.50 - $0.60+32.08%Beat+133.3%3N/AJul 26, 2018$31.52M
    Mar 31, 2018$0.30$0.27$0.20 - $0.30+11.11%Beat+50.0%3N/AMay 2, 2018$26.76M
    Dec 31, 2017$0.05$0.05$0.05 - $0.060.00%In line+25.0%3N/AMar 1, 2018$21.65M
    Sep 30, 2017$0.30$0.33N/A-9.09%Miss0.0%N/AN/AOct 26, 2017$18.72M
    Jun 30, 2017$0.30$0.30N/A0.00%In line0.0%N/AN/AJul 27, 2017$18.96M
    Mar 31, 2017$0.20$0.13N/A+53.85%Beat-60.0%N/AN/AApr 27, 2017$18.09M
    Dec 31, 2016$0.04$0.04N/A0.00%In lineN/AN/AN/AMar 9, 2017$26.41M
    Last 40 quarters

    Annual EPS

    EPS for the fiscal year ended Dec 31, 2025 was -$0.87, after -$0.03 the year before. It was $1.14 for the year ended Dec 31, 2016, the oldest of the 10 fiscal years shown.

    Fiscal year endedEPSChange
    Dec 31, 2025-$0.87N/A
    Dec 31, 2024-$0.03-102.4%
    Dec 31, 2023$1.14+35.7%
    Dec 31, 2022$0.84-52.8%
    Dec 31, 2021$1.78+102.3%
    Dec 31, 2020$0.88-18.5%
    Dec 31, 2019$1.08-26.5%
    Dec 31, 2018$1.47+72.9%
    Dec 31, 2017$0.85-25.4%
    Dec 31, 2016$1.14N/A

    Earnings Calls

    The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 3,600 words across 7 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q3Sep 30, 20263,6037
    2026Q2Jun 30, 20262,8766
    2026Q1Mar 31, 20262,7556
    2025Q4Dec 31, 20253,1266
    2025Q3Sep 30, 20252,6786
    2025Q2Jun 30, 20252,6836
    2025Q1Mar 31, 20254,1446
    2024Q4Dec 31, 20244,3266

    2026Q3 Earnings Call

    Opening remarks

    Taylor Krafchik Senior Vice President Thank you, operator. Good morning, everyone. Thank you for joining the Harvard Bioscience Third Quarter 2026 Earnings Conference Call. Leading the call today will be John Duke, President and Chief Executive Officer, and Mark Frost, Chief Financial Officer. In conjunction with today's recorded call, we have provided a presentation that will be referenced during our remarks, which is posted to the Investor Relations section of our website at investor.harvardbioscience.com. Please note that statements made in today's discussion that are not historical facts, including statements on management's expectations of future events or future financial performance, are forward-looking statements and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements reflect the current views of Harvard Bioscience's management, and Harvard Bioscience assumes no obligation to update or revise any forward-looking statements. Actual results may differ materially from those expressed or implied. Please refer to today's press release, the Harvard Bioscience Form 10-Q, and other filings with the Securities and Exchange Commission for additional disclosures on forward-looking statements and the risks, uncertainties, and contingencies associated therewith. During the call, management will also reference certain non-GAAP financial measures, which can be useful in evaluating the company's operations related to our financial condition and results. These non-GAAP measures are intended to supplement GAAP financial information and should not be considered a substitute. Reconciliations of GAAP to non-GAAP measures are provided in today's earnings press release. I will now turn the call over to John. John, please go ahead.

    John Duke President and Chief Executive Officer Thank you, Taylor, and good morning, everyone. In the third quarter, we delivered another solid quarter of top-line performance with 8% revenue growth, driven by strength across key preclinical platforms and double-digit momentum in products for organoids, fluidics, and our new product innovation. To give a high-level summary before Mark dives into the detailed financials, our results were in line with our expectations. Revenue came in at $22.2 million, representing 8% growth year over year, marking our second consecutive quarter of strong revenue growth. Adjusted gross margin was 57.1%, including higher volume in CMT products, increased sales through distribution partners, and growth in China, which carried lower gross margins. Adjusted EBITDA was $1.8 million, reflecting the same factors that impacted gross margin. Strong sales to CRO customers were driven by sales of our telemetry, respiratory, and inhalation products. CRO sales are up meaningfully year to date, reflecting healthy demand as biopharma customers increasingly rely on external research partners. We also saw continued growth from our biopharma customers. Across the broader drug development landscape, industry tailwinds remain supportive of future growth.

    Frequently Asked Questions About HBIO

    Did HBIO beat earnings estimates last quarter?

    Yes. Harvard Bioscience reported EPS of -$0.16 for the quarter ended Sep 30, 2026, above the -$0.65 estimate, a 75.38% surprise.

    What EPS do analysts expect from HBIO next quarter?

    The consensus EPS estimate for Harvard Bioscience for the quarter ending Dec 31, 2026 is $0.19 from 4 analysts, with estimates from $0.08 to $0.32.

    How often does HBIO beat earnings estimates?

    Harvard Bioscience beat the EPS estimate in 4 of the 8 most recent quarters that had an estimate, with an average surprise of -23.60%.